1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with nafamostat in 1 studies
Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (nafamostat) | Trials (nafamostat) | Recent Studies (post-2010) (nafamostat) |
---|---|---|---|---|---|
9,156 | 187 | 552 | 640 | 54 | 198 |
Protein | Taxonomy | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) | nafamostat (IC50) |
---|---|---|---|
Ubiquitin-like modifier activating enzyme 2 | Homo sapiens (human) | 7.47 | |
SUMO1 activating enzyme subunit 1 | Homo sapiens (human) | 7.47 | |
ubiquitin-like modifier-activating enzyme 1 | Homo sapiens (human) | 14 | |
SUMO-conjugating enzyme UBC9 | Homo sapiens (human) | 7.47 | |
ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | 14 | |
ubiquitin-conjugating enzyme E2 variant 1 isoform a | Homo sapiens (human) | 14 | |
Prothrombin | Homo sapiens (human) | 1.9 | |
Complement C1r subcomponent | Homo sapiens (human) | 0.8 | |
Plasminogen | Homo sapiens (human) | 2.9 | |
Cationic trypsin | Bos taurus (cattle) | 0.017 | |
Serine protease hepsin | Homo sapiens (human) | 0.005 | |
Trypsin-1 | Homo sapiens (human) | 0.017 | |
Complement C1s subcomponent | Homo sapiens (human) | 0.029 | |
Hepatocyte growth factor activator | Homo sapiens (human) | 0.15 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fukui, K; Koyama, M; Munakata, M; Ono, Y; Satoh, K; Suzuki, S | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and nafamostat
Article | Year |
---|---|
Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure.
Topics: Animals; Antithrombins; Benzamidines; Dogs; Guanidines; Heart Failure; Heart-Assist Devices; Hemofiltration; Platelet Activating Factor; Protease Inhibitors; Ventricular Function, Left | 2000 |